EAU Bladder Cancer Recurrence Risk (EORTC)
EORTC recurrence score for non-muscle-invasive bladder cancer (Ta/T1) after TURBT: probability of recurrence at 1 and 5 years. Progression risk uses a separate EORTC score with different weights.
Score interpretation
EORTC recurrence probability 15 % at 1 year, 31 % at 5 years.
→ Single instillation intravesical mitomycin C within 24h of TURBT; cystoscopy at 3 months, then annually if negative
EORTC recurrence probability 24 % at 1 year, 46 % at 5 years.
→ Adjuvant intravesical BCG or mitomycin C (6–12 inductions); cystoscopy at 3, 6, 12 months then annually
EORTC recurrence probability 38 % at 1 year, 62 % at 5 years.
→ Adjuvant intravesical BCG or mitomycin C (6–12 inductions); cystoscopy at 3, 6, 12 months then annually
EORTC recurrence probability 61 % at 1 year, 78 % at 5 years.
→ BCG induction + 1–3 year maintenance; consider radical cystectomy if T1G3 + CIS; cystoscopy every 3 months for 2 years
Interpretation bands for the Bladder Ca Risk. Apply clinical judgement and local guidance.
References
- Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. Eur Urol. 2006;49(3):466-475.
Related
Curated clinical cross-links plus same-class fallbacks.
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Mirabegron (Overactive Bladder — Elderly) · Beta-3 Adrenoceptor Agonist
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.